TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)
September 17, 2024 5:54 AM EDTPiper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $11.00 price target on Sutro Biopharma (NASDAQ: STRO).
The analyst comments "At ESMO, initial Phase I/II data on 4.3mg/kg q3W luvelta in combination with Avastin (bevacizumab) achieved impressive 56% (5/9) ORR in late-stage... More
